AR097067A1 - Formulación que comprende un agente hipolipidémico - Google Patents

Formulación que comprende un agente hipolipidémico

Info

Publication number
AR097067A1
AR097067A1 ARP140102777A ARP140102777A AR097067A1 AR 097067 A1 AR097067 A1 AR 097067A1 AR P140102777 A ARP140102777 A AR P140102777A AR P140102777 A ARP140102777 A AR P140102777A AR 097067 A1 AR097067 A1 AR 097067A1
Authority
AR
Argentina
Prior art keywords
hypolipidemic agent
formulation included
composition
formulation
alkalinizers
Prior art date
Application number
ARP140102777A
Other languages
English (en)
Inventor
Sheikh Shafiq
D Patel Jitendre
Patel Snehal
Davadra Prakash
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AR097067A1 publication Critical patent/AR097067A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica estable de compuestos de fórmula (1) o sus derivados, en la cual R se selecciona entre hidroxi, hidroxialquilo, acilo, alcoxi, alquiltio, tioalquilo, ariloxi, ariltio, y M⁺ representa cationes metálicos adecuados tales como Na⁺, K+, Ca⁺², Mg⁺² en donde el pH de la composición se mantiene a un valor por encima de 7, caracterizada porgue comprende: i) alcalinizadores adecuados o agentes modificadores del pH adecuados que mantienen el pH de la formulación por encima de 7 y, opcionalmente, ii) un estabilizador adecuado; y iii) uno o más excipientes farmacéuticamente aceptables adicionales.
ARP140102777A 2013-07-25 2014-07-25 Formulación que comprende un agente hipolipidémico AR097067A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (es) 2013-07-25 2013-07-25

Publications (1)

Publication Number Publication Date
AR097067A1 true AR097067A1 (es) 2016-02-17

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102777A AR097067A1 (es) 2013-07-25 2014-07-25 Formulación que comprende un agente hipolipidémico

Country Status (21)

Country Link
US (2) US9610277B2 (es)
EP (1) EP3024446A1 (es)
JP (1) JP2016523895A (es)
KR (1) KR101786843B1 (es)
CN (1) CN105407873A (es)
AP (1) AP2015008876A0 (es)
AR (1) AR097067A1 (es)
AU (1) AU2014294548B2 (es)
BR (1) BR112015031878A2 (es)
CA (1) CA2917923A1 (es)
EA (1) EA201690072A1 (es)
HK (1) HK1219222A1 (es)
IN (1) IN2013MU02470A (es)
MA (1) MA38865A1 (es)
MX (1) MX2015016971A (es)
NZ (1) NZ714558A (es)
PH (1) PH12015502802A1 (es)
SG (1) SG11201509798PA (es)
TW (1) TW201545773A (es)
WO (1) WO2015011730A1 (es)
ZA (1) ZA201508682B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8149178B2 (en) 2006-05-23 2012-04-03 Intel Corporation Millimeter-wave communication system with directional antenna and one or more millimeter-wave reflectors
MY191100A (en) 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
AU2013387996B2 (en) 2013-04-22 2015-12-10 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (NAFLD)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (es) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
EP3551180B1 (en) 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
US20220175721A1 (en) * 2019-02-13 2022-06-09 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
US20220169603A1 (en) * 2019-03-11 2022-06-02 Cadila Healthcare Ltd. Novel salts, crystalline forms and premix of hypolipidemic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0648212B1 (en) 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
WO1996033998A1 (fr) 1995-04-28 1996-10-31 Daiichi Pharmaceutical Co., Ltd. Composes pentacycliques
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
EP1124807A1 (en) 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1073643B1 (en) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
PL341795A1 (en) 1998-05-27 2001-05-07 Reddy Research Foundation Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
AU6325899A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
WO2001053257A2 (en) 2000-01-19 2001-07-26 Cadila Healthcare Ltd. Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
US20070051626A1 (en) 2003-09-26 2007-03-08 Chiho Itou Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
WO2005095381A1 (en) 2004-03-15 2005-10-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ATE482700T1 (de) * 2006-02-22 2010-10-15 Eisai R&D Man Co Ltd Stabilisierte pharmazeutische zusammensetzung
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
EP2641596B1 (en) 2009-11-26 2018-05-02 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EP2627323A4 (en) * 2010-10-12 2014-03-12 Univ Johns Hopkins ANTITUSSIVE COMPOSITIONS COMPRISING MÉMANTINE
MY191100A (en) * 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
AU2013387996B2 (en) * 2013-04-22 2015-12-10 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (NAFLD)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (es) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
EP3039011A1 (en) 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (es) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
MX2015016971A (es) 2016-04-25
TW201545773A (zh) 2015-12-16
CA2917923A1 (en) 2015-01-29
AU2014294548A1 (en) 2015-12-17
EA201690072A1 (ru) 2016-06-30
KR101786843B1 (ko) 2017-10-18
EP3024446A1 (en) 2016-06-01
SG11201509798PA (en) 2016-02-26
HK1219222A1 (zh) 2017-03-31
MA38865A1 (fr) 2017-12-29
US20160136131A1 (en) 2016-05-19
AP2015008876A0 (en) 2015-11-30
JP2016523895A (ja) 2016-08-12
WO2015011730A1 (en) 2015-01-29
US20170266158A1 (en) 2017-09-21
IN2013MU02470A (es) 2015-06-26
US9610277B2 (en) 2017-04-04
BR112015031878A2 (pt) 2017-07-25
KR20160013150A (ko) 2016-02-03
US10098868B2 (en) 2018-10-16
CN105407873A (zh) 2016-03-16
NZ714558A (en) 2017-02-24
PH12015502802A1 (en) 2016-03-14
ZA201508682B (en) 2017-03-29
AU2014294548B2 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
AR097067A1 (es) Formulación que comprende un agente hipolipidémico
PE20171238A1 (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
BR112018075259A2 (pt) composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
MY189761A (en) Quinazoline derivatives used to treat hiv
PE20151786A1 (es) Compuestos heterociclicos y sus usos
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
BR112018006025A2 (pt) composição farmacêutica e aplicação da mesma
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
MY197626A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
CY1119694T1 (el) Ημιθειικο αλας του 5,10-μεθυλενο-(6r)-τετραϋδροφυλλικου οξεος
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
MX2016008977A (es) Formulaciones farmaceuticas de insulina aspart estabilizadas.
DOP2016000007A (es) Pirazolpiridinas sustituidas
PH12018500378A1 (en) Novel annelated phenoxyacetamides
BR112018075221A2 (pt) micropartículas compreendendo um composto contendo enxofre
PE20170523A1 (es) Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.

Legal Events

Date Code Title Description
FB Suspension of granting procedure